title: Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
abstract: BACKGROUND
  Antipsychotic monotherapy is considered the gold standard in pharmacological treatment of schizophrenia and other psychotic disorders. Only 2 of the main clinical guides recommend the use of antipsychotic polypharmacy (AP) for those patients refractory to monotherapy. Nonetheless, there is a large rate of studies, conducted in many different settings, showing that AP is more frequent as would be expected attending experts' recommendations.
  
  
  METHODS
  In this retrospective study, we review all the psychotropic drugs dispensed to inpatients of a brief hospitalization psychiatric unit diagnosed as having schizophrenia or schizoaffective disorder (International Statistical Classification of Diseases, 10th Revision) at time of discharge in the year 2005. These included a total of 209 patients older than 18 years.
  
  
  RESULTS
  Of the 209 studied patients, 55.5% were discharged under AP treatment. Inpatients were given a mean of 3.06 psychotropic drugs and a mean of 1.61 antipsychotics at the time of hospital discharge. A total of 33.2% of the studied patients got anticholinergic drugs, and 66.2% were given benzodiazepines. The most prevalent combination of drugs was intramuscular long-acting risperidone plus an atypical antipsychotic. Amisulpride was the most used antipsychotic as adjuvant treatment.
  
  
  CONCLUSIONS
  Despite different clinical guidelines, AP is a common pharmacological strategy as it is shown in our study and in the reviewed literature. Data in our study indicate that the observed rates of AP cannot exclusively be attributed to the treatment of patients with clozapine-resistant schizophrenia.
authors.affiliation: Acute Inpatients Unit, Dr. R. Lafora Psychiatric Hospital, Madrid, Spain. ivanlerma810@hotmail.com
authors.forename: Ivan
authors.initials: I
authors.lastname: Lerma-Carrillo
authors.forename: Silvia
authors.initials: S
authors.lastname: de Pablo Brühlmann
authors.forename: Marta Leonor
authors.initials: ML
authors.lastname: del Pozo
authors.forename: Fernando
authors.initials: F
authors.lastname: Pascual-Pinazo
authors.forename: Juan D
authors.initials: JD
authors.lastname: Molina
authors.forename: Enrique
authors.initials: E
authors.lastname: Baca-García
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D019338:Polypharmacy; D011567:Psychiatric Department, Hospital; D011618:Psychotic Disorders / Q000188:drug therapy*; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents